WO2025134050 - TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D AND CD3 FOR THE TREATMENT OF MULTIPLE MYELOMA
National phase entry is expected:
Publication Number
WO/2025/134050
Publication Date
26.06.2025
International Application No.
PCT/IB2024/063022
International Filing Date
20.12.2024
Title **
[English]
TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D AND CD3 FOR THE TREATMENT OF MULTIPLE MYELOMA
[French]
ANTICORPS TRISPÉCIFIQUE CIBLANT BCMA, GPRC5D ET CD3 POUR LE TRAITEMENT DU MYÉLOME MULTIPLE
Applicants **
JANSSEN BIOTECH, INC
Inventors
LEE, Sangmin
GOLDBERG, Jenna
SMIT, Marie-Anne Damiette
DASKALAKIS, Nikki
WEIDMAN, Joseph Warren
NGUYEN, Ashley
KREVVATA, Maria
HUTNICK, Natalie
DEANGELIS, Nikki Alaina
ELSAYED, Yusri Ali
Priority Data
63/613,454
21.12.2023
US
63/660,768
17.06.2024
US
63/695,975
18.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7034 | |
| EPO | Filing, Examination, Granting | 100505 | |
| Japan | Filing, Examination, Granting | 4787 | |
| South Korea | Filing, Examination, Granting | 7570 | |
| USA | Filing, Examination, Granting | 23990 |
Total:
143,886
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Embodiments of the present disclosure relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of a BCMA x GPRC5D x CD3 trispecific antibody or trispecific binding fragment thereof, to the subject to the subject to treat the multiple myeloma.[French]
Des modes de réalisation de la présente divulgation concernent des méthodes de traitement du myélome multiple chez un sujet en ayant besoin, comprenant l'administration d'une quantité thérapeutiquement efficace d'un anticorps trispécifique ciblant BCMA x GPRC5D x CD3 ou d'un fragment de liaison trispécifique de celui-ci au sujet pour traiter le myélome multiple.